Article
Autotaxin Inhibition Ameliorates HFpEF Phenotype By Reducing LPA-Mediated Systemic Inflammation And Cardiac Remodeling
2026-08-30
Abstract excerpt
<h4>Background: </h4> HFpEF accounts for roughly half of heart failure admissions and lacks disease-modifying therapy. Autotaxin (ENPP2) generates lysophosphatidic acid (LPA), a profibrotic and pro-inflammatory bioactive lipid. Whether circulating lysophospholipid metabolism is altered in HFpEF, and whether autotaxin inhibition modifies an established experimental HFpEF phenotype, is untested. <h4>Methods:</h4> Pl...
Identifiers and source
- Literature Corpus work
- 011ca061-95ba-566a-b213-138b4db87ae5
- DOI
- 10.64898/2026.08.26.747366
